Trevi Therapeutics’ Haduvio shows cough relief efficacy in Phase 2a trial

Trevi Therapeutics, developing investigational therapy Haduvio – oral nalbuphine – for the treatment of chronic cough in idiopathic pulmonary fibrosis – IPF – and refractory chronic cough – RCC -, announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston from October 6-9. The presentation will include cough data from 38 IPF patients who completed at least 1 treatment period of the CANAL trial. Results demonstrated a significant increase in relief-of-cough time, reduced cough time, and reduced cough intensity in IPF patients with nalbuphine ER compared with placebo. The safety results of the trial were generally consistent with the known safety profile of nalbuphine ER from previous trials. The most frequently reported treatment-emergent adverse events with nalbuphine ER treatment were nausea, dizziness, anxiety, constipation, vomiting, dry mouth, headache, somnolence, dyspnea, decreased appetite, fatigue and lethargy.